[go: up one dir, main page]

ES2091941T3 - Potenciador del efecto antineoplasico y agente antineoplasico. - Google Patents

Potenciador del efecto antineoplasico y agente antineoplasico.

Info

Publication number
ES2091941T3
ES2091941T3 ES91915614T ES91915614T ES2091941T3 ES 2091941 T3 ES2091941 T3 ES 2091941T3 ES 91915614 T ES91915614 T ES 91915614T ES 91915614 T ES91915614 T ES 91915614T ES 2091941 T3 ES2091941 T3 ES 2091941T3
Authority
ES
Spain
Prior art keywords
antineoplasic
antineoplastic
potentiating
agent
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91915614T
Other languages
English (en)
Inventor
Junji Uchida
Hiroyuki Okabe
Teiji Takechi
Setsuo Takeda
Yuji Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17034249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2091941(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2091941T3 publication Critical patent/ES2091941T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

UN POTENCIADOR DEL EFECTO ANTINEOPLASTICO PARA UN AGENTE ANTINEOPLASTICO QUE CONTIENE TEGAFUR EN UNA CANTIDAD FARMACEUTICAMENTE EFECTIVA Y URACIL EN UNA CANTIDAD EFECTIVA EN LA POTENCIACION DEL EFECTO ANTINEOPLASTICO, QUE CONTIENE COMO INGREDIENTE ACTIVO ACIDO OLINICO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO EN UNA CANTIDAD EFECTIVA EN LA POTENCIACION DEL EFECTO ANTINEOPLASTICO; UN AGENTE ANTINEOPLASTICO QUE CONTIENE TEGAFUR EN UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA, URACIL EN UNA CANTIDAD EFECTIVA EN LA POTENCIACION DEL EFECTO ANTINEOPLASTICO, Y ACIDO FOLINICO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO EN UNA CANTIDAD EFECTIVA EN LA POTENCIACION DEL EFECTO ANTINEOPLASTICO; UN METODO DE POTENCIAR EL EFECTO ANTINEOPLASTICO DE UN AGENTE ANTINEOPLASTICO MEDIANTE LA ADMINISTRACION DE DICHO POTENCIADOR A LOS PACIENTES; Y UN METODO PARA TRATAR CANCERES DE MAMA MEDIANTE LA ADMINISTRACION DE DICHO AGENTE A LOS PACIENTES.
ES91915614T 1990-09-07 1991-09-05 Potenciador del efecto antineoplasico y agente antineoplasico. Expired - Lifetime ES2091941T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23871990 1990-09-07

Publications (1)

Publication Number Publication Date
ES2091941T3 true ES2091941T3 (es) 1996-11-16

Family

ID=17034249

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91915614T Expired - Lifetime ES2091941T3 (es) 1990-09-07 1991-09-05 Potenciador del efecto antineoplasico y agente antineoplasico.

Country Status (14)

Country Link
EP (1) EP0500953B1 (es)
JP (1) JP2557303B2 (es)
KR (1) KR0146952B1 (es)
AT (1) ATE141506T1 (es)
AU (1) AU644684B2 (es)
CA (1) CA2071819A1 (es)
DE (2) DE10299023I2 (es)
DK (1) DK0500953T3 (es)
ES (1) ES2091941T3 (es)
GR (1) GR3021003T3 (es)
HU (1) HU211739A9 (es)
LU (1) LU90791I2 (es)
NL (1) NL300041I2 (es)
WO (1) WO1992004028A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05310573A (ja) * 1992-05-01 1993-11-22 Dotsuto:Kk リウマチ治療薬
US5643191A (en) * 1995-01-26 1997-07-01 Sorin Biomedical Inc. Cardioplegia delivery system and method for converting from warm cardioplegia to cold cardioplegia
US5702358A (en) * 1995-02-23 1997-12-30 Sorin Biomedical Inc. Cardioplegia delivery apparatus and method of use
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US6538001B1 (en) * 1998-10-12 2003-03-25 Nikolai Borisovich Leonidov Crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl) uracil and complex compounds based thereon, producing antineoplastic effect
US9611227B2 (en) * 2003-03-14 2017-04-04 Taiho Pharmaceutical Co., Ltd. Antitumor effect potentiator and antitumor agent
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
AU2008356312B2 (en) 2008-05-12 2015-04-09 Shizuoka Prefecture Antitumor agent, kit, and method for treating cancer
KR102258514B1 (ko) * 2019-09-23 2021-05-31 연세대학교 산학협력단 신규한 다층형 좌약 제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5953885B2 (ja) * 1978-02-10 1984-12-27 大鵬薬品工業株式会社 抗腫瘍剤組成物
GB2016921B (en) * 1978-03-27 1982-08-18 Taiho Pharmaceutical Co Ltd Anti cancer compositions containing uracil derivatives
JPS5780319A (en) * 1980-11-06 1982-05-19 Taiho Yakuhin Kogyo Kk Anti-tumor agent having reduced toxicity

Also Published As

Publication number Publication date
AU8447991A (en) 1992-03-30
DE69121551T2 (de) 1997-01-02
HU211739A9 (en) 1995-12-28
NL300041I1 (nl) 2001-06-01
ATE141506T1 (de) 1996-09-15
CA2071819A1 (en) 1992-03-08
JP2557303B2 (ja) 1996-11-27
GR3021003T3 (en) 1996-12-31
WO1992004028A1 (en) 1992-03-19
KR927002224A (ko) 1992-09-03
DE69121551D1 (de) 1996-09-26
AU644684B2 (en) 1993-12-16
EP0500953A1 (en) 1992-09-02
DE10299023I1 (de) 2003-06-05
LU90791I2 (fr) 2001-10-08
KR0146952B1 (ko) 1998-08-17
NL300041I2 (nl) 2002-02-01
DE10299023I2 (de) 2010-05-06
EP0500953B1 (en) 1996-08-21
EP0500953A4 (en) 1993-04-21
DK0500953T3 (da) 1997-01-06

Similar Documents

Publication Publication Date Title
FI862011A0 (fi) Terapeutiska nukleosider.
HU9302496D0 (en) Method for producing anti-viral nucleoside combinations and one for preparing medical preparatives containing said compounds
NL970006I2 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
SE8801729D0 (sv) Purine derivatives for use in therapy
EP0620004A4 (en) MEDICAL COMPOSITION.
ES2091941T3 (es) Potenciador del efecto antineoplasico y agente antineoplasico.
DE3875769D1 (de) Therapeutische nukleoside.
WO1990014831A3 (en) 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
DE69130063D1 (de) Antivirales arzneimittel enthaltend prostratin
BG100599A (en) Antiviral form and therapeutical method
IL97054A0 (en) Pharmaceutical compositions comprising buspirones for the treatment of sleep apneas
NO810480L (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater
GR3029886T3 (en) Method of preparing a radioactive rhenium complex solution.
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
PT728002E (pt) Utilizacao de derivados de 2-amino purina para o tratamento e profilaxia da infeccao pelo virus de herpes 7 humano
WO1990006116A3 (de) Mittel zur behandlung von chronisch entzündlichen darmerkrankungen
DK0814813T3 (da) Anvendelse af penciclovir til behandling af human herpesvirus-8
ES2062752T3 (es) Preparado de una sal de oxipurinol en forma oral para el tratamiento de hiperuricemia.
DE69228945D1 (de) Pharmazeutische pentapeptid-zusammensetzung und ihre verwendung
CY2338B1 (en) Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections.
CA2153570A1 (en) Pharmaceutical composition for treating nicotine dependence
IT1243368B (it) Uso del bendazac e dei suoi sali farmaceuticamente accettabili

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 500953

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: TEGAFUR + URACILO (UFT)

Spc suppl protection certif: C200000019

Filing date: 20000921

SPCG Supplementary protection certificate granted

Free format text: TEGAFUR + URACILO (UFT)

Spc suppl protection certif: C200000019

Filing date: 20000921

Expiry date: 20150323

Effective date: 20030901